List of Astex Therapeutics Limited patents

Patents where

Current Assignee

Name

‌

Astex Therapeutics Limited

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10085982 Combinations	Patent 10085982 was granted and assigned to Astex Therapeutics Limited on October, 2018 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	10085982	October 2, 2018
‌ US Patent 8399442 Pharmaceutical compounds	Patent 8399442 was granted and assigned to Astex Therapeutics Limited on March, 2013 by the United States Patent and Trademark Office.		‌ Astex Therapeutics Limited	United States Patent and Trademark Office	8399442	March 19, 2013
‌ US Patent 9464071 Pyrazolyl quinoxaline kinase inhibitors	Patent 9464071 was granted and assigned to Astex Therapeutics Limited on October, 2016 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	9464071	October 11, 2016
‌ US Patent 9850228 Pyrazolyl quinoxaline kinase inhibitors	Patent 9850228 was granted and assigned to Astex Therapeutics Limited on December, 2017 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	9850228	December 26, 2017
‌ US Patent 10898482 Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine	Patent 10898482 was granted and assigned to Astex Therapeutics Limited on January, 2021 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	10898482	January 26, 2021
‌ US Patent 10478494 FGFR/PD-1 combination therapy for the treatment of cancer	Patent 10478494 was granted and assigned to Astex Therapeutics Limited on November, 2019 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	10478494	November 19, 2019
‌ US Patent 7149280 Synthesis and screening of ligands using X-ray crystallography	Patent 7149280 was granted and assigned to Astex Therapeutics Limited on December, 2006 by the United States Patent and Trademark Office.		‌ Astex Therapeutics Limited	United States Patent and Trademark Office	7149280	December 12, 2006
‌ US Patent 10272087 Pteridines as FGFR inhibitors	Patent 10272087 was granted and assigned to Astex Therapeutics Limited on April, 2019 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	10272087	April 30, 2019
‌ US Patent 10421747 Quinoxaline derivatives useful as FGFR kinase modulators	Patent 10421747 was granted and assigned to Astex Therapeutics Limited on September, 2019 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	10421747	September 24, 2019
‌ US Patent 9458158 Bicyclic heterocycle compounds and their uses in therapy	Patent 9458158 was granted and assigned to Astex Therapeutics Limited on October, 2016 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	9458158	October 4, 2016
‌ US Patent 10039759 Quinolines as FGFR kinase modulators	Patent 10039759 was granted and assigned to Astex Therapeutics Limited on August, 2018 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	10039759	August 7, 2018
‌ US Patent 8895601 Pyrazolyl quinoxaline kinase inhibitors	Patent 8895601 was granted and assigned to Astex Therapeutics Limited on November, 2014 by the United States Patent and Trademark Office.		‌ Astex Therapeutics Limited	United States Patent and Trademark Office	8895601	November 25, 2014
‌ US Patent 9447098 Pteridines as FGFR inhibitors	Patent 9447098 was granted and assigned to Astex Therapeutics Limited on September, 2016 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	9447098	September 20, 2016
‌ US Patent 9309242 Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors	Patent 9309242 was granted and assigned to Astex Therapeutics Limited on April, 2016 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	9309242	April 12, 2016
‌ US Patent 9303029 Substituted quinoxalines as FGFR kinase inhibitors	Patent 9303029 was granted and assigned to Astex Therapeutics Limited on April, 2016 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	9303029	April 5, 2016
‌ US Patent 9018214 Bicyclic heterocycle compounds and their uses in therapy	Patent 9018214 was granted and assigned to Astex Therapeutics Limited on April, 2015 by the United States Patent and Trademark Office.		‌ Astex Therapeutics Limited	United States Patent and Trademark Office	9018214	April 28, 2015
‌ US Patent 10045982 Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors	Patent 10045982 was granted and assigned to Astex Therapeutics Limited on August, 2018 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	10045982	August 14, 2018
‌ US Patent 10052320 Substituted quinoxalines as FGFR kinase inhibitors	Patent 10052320 was granted and assigned to Astex Therapeutics Limited on August, 2018 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	10052320	August 21, 2018
‌ US Patent 11225476 Bicyclic heterocycle compounds and their uses in therapy	Patent 11225476 was granted and assigned to Astex Therapeutics Limited on January, 2022 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	11225476	January 18, 2022
‌ US Patent 9617283 Bicyclic heterocycle compounds and their uses in therapy	Patent 9617283 was granted and assigned to Astex Therapeutics Limited on April, 2017 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	9617283	April 11, 2017
‌ US Patent 10519137 Pyrazolyl quinoxaline kinase inhibitors	Patent 10519137 was granted and assigned to Astex Therapeutics Limited on December, 2019 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	10519137	December 31, 2019
‌ US Patent 9155743 Bicyclic heterocycle compounds and their uses in therapy	Patent 9155743 was granted and assigned to Astex Therapeutics Limited on October, 2015 by the United States Patent and Trademark Office.		‌ Astex Therapeutics Limited	United States Patent and Trademark Office	9155743	October 13, 2015
‌ US Patent 9617248 Bicyclic heterocycle compounds and their uses in therapy	Patent 9617248 was granted and assigned to Astex Therapeutics Limited on April, 2017 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	9617248	April 11, 2017
‌ US Patent 9783538 Bicyclic heterocycle compounds and their uses in therapy	Patent 9783538 was granted and assigned to Astex Therapeutics Limited on October, 2017 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	9783538	October 10, 2017
‌ US Patent 9303030 Compounds	Patent 9303030 was granted and assigned to Astex Therapeutics Limited on April, 2016 by the United States Patent and Trademark Office.	‌ Astex Therapeutics Limited	‌ Astex Therapeutics Limited	United States Patent and Trademark Office	9303030	April 5, 2016

Results per page:

87 results

0 selected

87 results

0 selected